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the circuitry that regulates food intake
and body weight, particularly in the
context of such ubiquitous systems.
Future work in which either loss- or
gain-of-function manipulations can be
directed to specific cell populations,
rather than anatomical locations, will
provide further key insights to the
specific role of Hap1 in regulating energy
balance.
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P R E V I E W SRinging the dinner bell for insulin: Muscarinic M3
receptor activity in the control of pancreatic b cell function
In this issue ofCell Metabolism, Gautam et al. (2006) show that pancreatic b cell M3 muscarinic acetylcholine receptors con-
trol insulin secretion. Their results highlight the role of theM3 receptor subtype in integrating nervous stimuli with metabolic
control of insulin secretion and glucose homeostasis.In addition to glucose, insulin secretion
from the endocrine pancreatic b cells is
stimulated by several neuropeptide hor-
mones and neurotransmitters, among
which acetylcholine, the muscarinic cho-
linergic receptor agonist, plays a promi-
nent role (Ahren, 2000; Gilon and Hen-
quin, 2001). Acetylcholine is released
during the preabsorptive and absorptive
phases of feeding from parasympathetic
(vagal) nerve endings present in the pan-
creatic islet (Ahren, 2000; Gilon and Hen-
quin, 2001). The insulinotropic effects of
acetylcholine result from two comple-
mentary mechanisms: One involves
stimulation of inositol phosphate produc-
tion and a rise in the cytoplasmic Ca2+
concentration, whereas the other in-
volves a protein kinase C-mediated in-
crease in the efficiency of Ca2+ on exocy-
tosis of the insulin-containing granules
(Figure 1; for review, see Gilon and Hen-
quin, 2001). The increase in efferent para-
sympathetic outflow results from the con-
vergence and integration of redundant
nutrient-related signals, which include
central and peripheral neural inputs, as
well as hormonal and nutritional signals
(Ahren, 2000). In short, the nervous sys-390tem provides context for islet behavior,
optimizing the response of this endocrine
gland beyond what can be obtained with
glucose alone. The mechanisms underly-
ing this process are complex. In this is-
sue of Cell Metabolism, Gautam et al.
(2006) help clarify the role of the specific
M3 subtype of the muscarinic acetylcho-
line receptor family in glucose metabo-
lism in vivo.
At first glance, the involvement of ace-
tylcholine would seem to be a simple
matter to describe. However, despite de-
cades of study, the importance of acetyl-
choline in the maintenance of normal glu-
cose homeostasis remains unsettled.
Multiple muscarinic acetylcholine recep-
tor subtypes have been identified in the
b cell, making it difficult to assign specific
physiological functions to thehighlyabun-
dant M3 receptor. Additionally, peripheral
parasympathetic nerves release at least
five different neurotransmitters (all active
in the b cell and stimulating insulin secre-
tion), and most tissues or cell types ex-
press two or more muscarinic receptor
subtypes. Finally, increased parasympa-
thetic outflow also governs activities in
many other organs and tissues that haveimportant metabolic functions. This be-
came particularly obvious from studies
in mice with whole body deficiency of
the M3 muscarinic receptor, in which im-
pairments in insulin secretion were ob-
served in parallel with a paradoxical re-
duction in blood glucose levels. While
seemingly contradictory, the improve-
ment in glycemic control was most likely
due to a reduction in plasma glucagon
levels and reduced food intake (Yamada
et al., 2001; Duttaroy et al., 2004). Clearly,
to study the specific role played in vivo by
the b cell M3 receptor, one needs better
animal models (cell-specific knockouts)
or very precise pharmacological tools.
Gautam et al. (2006) now report the
generation of mutant mice selectively
lacking M3 muscarinic receptors in pan-
creatic b cells. These mice display im-
paired glucose tolerance and a dramatic
reduction in insulin secretion, thus dem-
onstrating that the activity of the b cell
M3 muscarinic receptors is essential
for maintaining normal glucose homeo-
stasis. It is well accepted that the acetyl-
choline-mediated preabsorptive phase
of insulin secretion (also called the ce-
phalic phase, not far removed from theCELL METABOLISM : JUNE 2006
P R E V I E W SFigure 1. Mechanisms by which acetylcholine stimulates insulin secretion in the preabsorptive and absorptive
phase in food intake
A) The preabsorptive insulin phase corresponds to the earliest plasma insulin rise during the first minutes of
food ingestion. It does not depend on nutrient assimilation, as it occurs before glycemia has increased, but
results from vagus nerve activation by the brain in response to input from sensory organs, including those
of the oral cavity and the visual and olfactory systems. Acetylcholine (ACh) is released from intrapancreatic
nerve endings and stimulates insulin secretion.
B) During the absorptive phase in food intake, insulin secretion is stimulated by direct mechanisms including
nutrients and the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing
peptide (GIP). Activation of glucoreceptors in the gut, brain, and liver increase vagal tone. The increase in ACh
release near the b cells in the pancreas amplifies nutrient-induced insulin secretion. Inset: At the b cell level,
ACh binds to M3 muscarinic receptors in the plasma membrane and activates several transduction pathways
(for review, see Gilon and Henquin, 2001); the major pathway is phospholipase C, which generates inositol tri-
sphosphate (IP3), leading to mobilization of intracellular Ca
2+ stores and diacylglycerol, a potent protein kinase
C (PKC) activator. A rise in the cytoplasmic Ca2+ concentration will stimulate insulin secretion, whereas PKC
increases the efficiency of Ca2+ on exocytosis of the insulin-containing granules.phenomenon illustrated by Pavlov’s sali-
vating dogs) seems to be of particular im-
portance for priming the liver and other
tissues to change their functions in antic-
ipation of the meal being absorbed
(Ahren, 2000; Gilon and Henquin, 2001).
However, Gautam et al. (2006) show that
the glucose-mediated activation of theCELL METABOLISM : JUNE 2006efferent parasympathetic nerves is not
a transient phenomenon associated
with the anticipation of eating but rather
persists throughout the absorptive phase
of a meal. Collectively, the data gener-
ated by Gautam et al. (2006) suggest
that the long-lasting increase in insulin
secretion following glucose-mediatedstimulation of efferent parasympathetic
nerves is mediated by M3 muscarinic
receptors on the pancreatic b cell and
seems essential for maintaining normal
glucose homeostasis.
To further test the system, Gautam
et al. (2006) generated transgenic mice
overexpressing the M3 muscarinic re-
ceptor specifically in the b cell. These
mice displayed lower glucose levels and
higher insulin levels in blood as com-
pared to control mice. The transgenic
mutant mice also resisted diet-induced
glucose intolerance. Together, these
findings in knockout and transgenic ani-
mals cleanly link insulin release and glu-
cose tolerance to the density of M3 mus-
carinic receptors in the pancreatic b cell.
These findings have several potentially
important clinical implications. For ex-
ample, regrowth and/or restoration of
the parasympathetic nervous supply to
whole pancreas transplants and trans-
planted islets may be an underappreci-
ated determinant of how well the trans-
planted tissue restores glycemic control
and maintains long-term glucose ho-
meostasis. The study by Gautam et al.
(2006) also suggests that antagonism of
the b cell M3 muscarinic receptor may
increase the risk of hyperglycemia and
diabetes in humans. Some antipsychotic
drugs have an increased risk of triggering
hyperglycemia and type 2 diabetes in
schizophrenic patients, which can occur
independently of the weight gain associ-
ated with these compounds (Barrett
et al., 2004). Accumulating evidence
links some antipsychotic agents with
a high binding affinity to M3 muscarinic
receptors and elevated risk for type 2 di-
abetes (Silvestra and Prous, 2005). In-
deed, M3 muscarinic receptor blockade
with antipsychotic drugs inhibits cholin-
ergic-stimulated insulin secretion (John-
son et al., 2005). Finally, islet autonomic
nerves have been implicated in the con-
trol of pulsatile insulin release (Ahren,
2000; Pørksen, 2002). This is probably
of clinical importance because both
impaired glucose tolerance and type 2
diabetes are characterized by disturbed
oscillatory patterns (Pørksen, 2002). The
role, if any, of the b cell M3 muscarinic
receptor for the synchronization of islet
function and pulsatile insulin release re-
mains to be determined but could be
studied using the b-M3-KO mice (Gau-
tam et al., 2006).
This study also raises a number of im-
portant questions. Perhaps foremost is391
P R E V I E W Sthe involvement of muscarinic choliner-
gic nerves in islet adaptation to insulin re-
sistance in humans and whether the fail-
ure of such a neural circuit results in the
development of impaired glucose toler-
ance or type 2 diabetes. It will also be
of interest to investigate the mechanisms
controlling M3 muscarinic receptor ex-
pression and to identify b cell M3 recep-
tor-associated cellular proteins. Increas-
ing M3 muscarinic receptor expression or
targeting such receptor-regulatory pro-
teins could lead to novel therapeutic con-
cepts for the treatment of patients with
impaired glucose tolerance or type 2 dia-
betes by selectively enhancing signaling
through the M3 muscarinic receptors in
the pancreatic b cell.392Jesper Gromada1
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